TABLE 1.
Production of LCMV-GP-pseudotyped oncoretroviral and lentiviral vectors
| Transfected plasmids | Pseudotype titer [TU/ml] (± SD)a |
|---|---|
| RV + MLVgagpol + LCMV GP | 1.3 (± 1.1) × 105 |
| RV + LCMV GP | <102b |
| RV + MLVgagpol | <102 |
| RV | <102 |
| LV + HIVgagpol + HIVrev + LCMV GP | 2.8 (± 2.3) × 105 |
| LV + LVgagpol+ HIVrev + LCMV GP | <102 |
| LV + LVgagpol + LCMV GP | <102 |
| LV + LCMV GP | <102 |
| LV | <102 |
a
Different combinations of LCMV-GP- and MLV-based oncoretroviral (RV) or HIV-based lentiviral (LV) packaging plasmids were cotransfected into 293T cells. Cell supernatants were analyzed by end-point dilutions on TE671 cells. Results are the mean vector titers and standard deviations of three experiments.
b
Vector titer was lower than the detection limit.